Anika Therapeutics posts 4Q18 orthobiologic revenue of USD $23.8MM, -5.3% vs. 4Q17, with 2018 full-year orthobiologic revenue of $93.6MM, -0.2% vs. 2017.
ORTHOWORLD expects the knee segment to remain a steady performer in the low single digits as price pressure erodes revenue from legacy products, but new technologies and products allow well-positioned companies to drive more favorable sales mix.
Sanofi reports 4Q18 Synvisc/Synvisc-One orthobiologics revenue of €81MM (USD $93.1MM), -5.8% vs. 4Q17, with 2018 full-year revenue of €313MM (USD $359.6MM), -19.1% vs. 2017.